• Royalty Pharma in its US$827 million acquisition of Ligand Pharmaceuticals’ royalties on sales of Promacta.
    • Prosecuting a patent portfolio and providing patent strategy advice for a French pharmaceutical company whose drug product, a combination of three known small molecule drugs, is in Phase 3 clinical trials for a rare genetic disease.
    • Drafting, filing, and prosecuting patent applications covering new uses and formulations of legacy in-licensed lead compound as well as new composition of matter applications for drug discovery program on behalf of Cambridge, Massachusetts-based pharmaceutical company.
    • Diligence evaluation of a US pharmaceutical company’s patent estate covering a cystic fibrosis small molecule drug candidate in the company’s US$88 million IPO.
    • Diligence evaluation of multiple patent estates covering small molecule drug candidates on behalf of a European pharmaceutical company in its US$275 million IPO.

    Includes matters handled at Dechert or prior to joining the firm.

    • 2020 Pro Bono High Honor Roll, Supreme Judicial Court of Massachusetts (awarded to individual attorneys who complete at least 100 hours of pro bono service during the previous year)
    • American Bar Association
    • American Intellectual Property Association